BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2025 8:44:58 AM | Browse: 12 | Download: 70
 |
Received |
|
2025-03-25 05:47 |
|
Peer-Review Started |
|
2025-03-25 05:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-09 12:50 |
|
Revised |
|
2025-04-21 20:15 |
|
Second Decision |
|
2025-06-09 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-09 07:03 |
|
Articles in Press |
|
2025-06-09 07:03 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-26 02:29 |
|
Publish the Manuscript Online |
|
2025-07-22 08:44 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Krzysztof Glaser, Wojciech Glaser, Luca Marino, Marek Ruchala and Federico Bilotta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Krzysztof Glaser, Doctorate Student, Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, Poznan 60-355, Poland. glaser.krzysztof@gmail.com |
| Key Words |
Glucagon-like peptide-1 receptor agonists; Antiobesity medication; Atrial fibrillation; Liraglutide; Semaglutide; Dulaglutide |
| Core Tip |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as potential therapeutic agents in atrial fibrillation (AF) management due to their cardiovascular benefits and weight-reducing effects. While semaglutide has shown promise in reducing AF incidence, liraglutide and dulaglutide have yielded inconsistent results. Compared to sodium-glucose co-transporter 2 inhibitors, which demonstrate more consistent AF reduction, GLP-1 RAs require further investigation to establish their role in AF prevention and management. |
| Publish Date |
2025-07-22 08:44 |
| Citation |
<p>Glaser K, Glaser W, Marino L, Ruchala M, Bilotta F. Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation. <i>World J Cardiol</i> 2025; 17(7): 107510</p> |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i7/107510.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i7.107510 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
